The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500 - 1/1000. Detects a band of approximately 34 kDa (predicted molecular weight: 35 kDa).
1/50 - 1/100.
Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
Belongs to the cyclin family. Cyclin D subfamily. Contains 1 cyclin N-terminal domain.
Nucleus. Cytoplasm. Membrane. Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members.
All lanes : Anti-Cyclin D3 antibody (ab63535) at 1/500 dilution
Lane 1 : Extracts from COS7 cells (5-30ug), treated
with Forskolin (40nM, 30mins), without immunising peptide. Lane 2 : Extracts from COS7 cells (5-30ug), treated
with Forskolin (40nM, 30mins), with immunising peptide (5-10ug).
Zhang X et al. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer. J Hematol Oncol10:29 (2017).
Read more (PubMed: 28114995) »